Source: MyndTec Inc.
  • MyndTec (MYTC) has launched a non-brokered private placement of up to 1,333,333 units
  • The units will be offered at a price of $0.75 per unit to raise aggregate gross proceeds to the company of up to $1,000,000
  • MyndTec intends to use the net proceeds of the offering to fund corporate expenditures, sales and marketing initiatives, and general working capital purposes
  • MyndTec Inc is a medical technology company
  • MyndTec Inc. (MYTC) opened trading at $0.90 per share

MyndTec (MYTC) has launched a non-brokered private placement for gross proceeds of up to $1,000,000.

The company will issue up to 1,333,333 units for $0.75 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant may be exercised to acquire one common share at an exercise price of $0.90 for a period of 36 months.

The company has the option to sell up to an additional 266,666 units for additional gross proceeds of up to $200,000.

MyndTec intends to use the net proceeds of the offering to fund corporate expenditures, sales and marketing initiatives, and general working capital purposes in respect of the development of the company’s two functional electrical stimulation (FES) products – MyndMoveand MyndStep.

All securities issued will be subject to a statutory hold period of four months from the closing date.

MyndTec Inc is a medical technology company. It researches, develops and distributes innovative therapies designed to improve function, maximize independence and enhance the quality of life for individuals with upper limb paralysis due to stroke, spinal cord injury or traumatic brain injury.

MyndTec Inc. (MYTC) opened trading at $0.90 per share.


More From The Market Online

Dream Water Kids Sleep Gummies set for US summer debut

Delivra Health (TSXV:DHB) will launch a new line of kids sleep gummies under its Dream Water brand across the US market this June.

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.